Ajanta Pharma Ltd. NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2800.50 -22.70 (-0.80%)

73,407

NSE+BSE Volume

NSE 30 Jul, 2025 3:31 PM (IST)

Estimates Miss

Ajanta Pharma's Q1FY26 net profit grows 3.9% YoY, but misses Forecaster estimates by 1.6% See details

Ajanta Pharma Ltd. share price target

Ajanta Pharma Ltd. has an average share price target of 3022. The consensus estimate represents an upside of 7.91% from the last price of 2800.50. View 9 reports from 5 analysts offering long-term price targets for Ajanta Pharma Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	31 Jul 2025	Ajanta Pharma	Consensus Share Price Target	2800.50	3009.83	-	7.47	buy	pdf Detailed Estimates
	16 Jun 2025	Ajanta Pharma	BP Wealth	2800.50	3140.00	2598.20 (7.79%)	12.12	Buy	pdf post cache		Broker Report BP Equities Ajanta Pharma Ltd. Shining Star Series BUY Target 3,140 BP Wealth pdf Copy Link Share on Share on Share on Share on Alert
	01 May 2025	Ajanta Pharma	ICICI Securities Limited Reco Target	2800.50	2500.00	2706.10 (3.49%)	Target met	Sell	pdf post cache		Broker Report Elevated cost to keep a check on margins ICICI Securities Limited Ajanta Pharma’s Q4FY25 result was in line with our expectations. Revenue growth of 11% YoY was primarily driven by India and US businesses while Africa institutional biz continues to be a drag (-54.1% YoY). pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2025	Ajanta Pharma	BOB Capital Markets Ltd. Target	2800.50	2288.00	2694.45 (3.94%)	18.30	Sell	pdf post cache		Broker Report Ajanta Pharma (SELL): Entering newer therapies to result in higher costs BOB Capital Markets Ltd. AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates pdf Copy Link Share on Share on Share on Share on Alert
	30 Jan 2025	Ajanta Pharma	Motilal Oswal Target	2800.50	3220.00	2676.85 (4.62%)	14.98	Buy	pdf post cache		Broker Report India/Asia drive earnings Motilal Oswal Ajanta Pharma (AJP) delivered a marginally better-than-expected performance in 3QFY25. It has continued to outperform in the Domestic Formulation (DF) market during this quarter. pdf Copy Link Share on Share on Share on Share on Alert
	11 Dec 2024	Ajanta Pharma	BOB Capital Markets Ltd. Reco Target	2800.50	2528.00	2793.70 (0.24%)	Target met	Sell	pdf post cache		Broker Report Ajanta Pharma (SELL): No incremental triggers; valuation expensive BOB Capital Markets Ltd. At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations pdf Copy Link Share on Share on Share on Share on Alert
	11 Nov 2024	Ajanta Pharma	ICICI Direct Target	2800.50	3455.00	2857.30 (-1.99%)	23.37	Buy	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	28 Oct 2024	Ajanta Pharma	Motilal Oswal Target	2800.50	3470.00	2922.60 (-4.18%)	23.91	Buy	pdf post cache		Broker Report Branded generics drive earnings Motilal Oswal Ajanta Pharma (AJP) delivered in-line performance in 2QFY25. Asia/Africa (47% of sales) grew strongly at 32% YoY in 2QFY25 due to superior execution and partly on the low base of the past year. pdf Copy Link Share on Share on Share on Share on Alert
	31 Jul 2024	Ajanta Pharma	ICICI Direct Target	2800.50	3165.00	2695.10 (3.91%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	30 Jul 2024	Ajanta Pharma	Motilal Oswal Target	2800.50	2935.00	2530.55 (10.67%)	Target met	Buy	pdf post cache		Broker Report Branded generics drive earnings Motilal Oswal Ajanta Pharma (AJP) delivered better-than-expected 1QFY25 performance, led by a superior show in the branded Africa segment, lower raw material costs, and controlled other expenses. pdf Copy Link Share on Share on Share on Share on Alert
	03 May 2024	Ajanta Pharma	BOB Capital Markets Ltd. Target	2800.50	2585.00	2383.85 (17.48%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Strong margins; growth momentum to continue BOB Capital Markets Ltd. Strong quarter with EBITDA/PAT beat of 8% each, led by reduction in API prices, logistics costs and reduced intensity of US price erosion pdf Copy Link Share on Share on Share on Share on Alert
	03 May 2024	Ajanta Pharma	ICICI Direct Target	2800.50	2875.00	2383.85 (17.48%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	02 May 2024	Ajanta Pharma	Motilal Oswal Target	2800.50	2565.00	2234.00 (25.36%)	Target met	Buy	pdf post cache		Broker Report Higher opex leads to EBITDA/PAT miss Motilal Oswal Ajanta Pharma (AJP) delivered in-line sales in 4QFY24. However, EBITDA/PAT came in lower than our expectations, due to higher opex and higher tax outgo. AJP continued to outperform the industry in domestic formulation (DF) and Asia market. The performance is expected to improve in the Africa branded generics market going forward. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2023	Ajanta Pharma	BOB Capital Markets Ltd. Target	2800.50	2070.00	1763.20 (58.83%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Buoyant margins but higher tax weighs on PAT BOB Capital Markets Ltd. Strong Q2 gross/EBITDA margins at 75%/28% drove a 7% EBITDA beat, though higher tax pulled PAT 2% below consensus pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2023	Ajanta Pharma	ICICI Securities Limited	2800.50	1870.00	1615.75 (73.33%)	Target met	Buy	pdf post cache		Broker Report Margin improvement story unfolding ICICI Securities Limited Ajanta Pharma’s Q1FY24 result surprised positively on margin front. Softening of raw material and freight costs have started showing improvement in gross (+482bps YoY) and EBITDA (+325bps) margins. Traction in India branded business continues to be robust, with 14% growth vs market growth rate of 9%, while momentum in export branded business is expected to gain in quarters ahead. pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2023	Ajanta Pharma	BOB Capital Markets Ltd. Target	2800.50	1860.00	1615.75 (73.33%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Q1 beat sparked by sharp margin recovery BOB Capital Markets Ltd. Strong Q1 beat with EBITDA/PAT of Rs 2.7bn/Rs 2.1bn coming in 17%/ 39% ahead of consensus due to margin recovery pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2023	Ajanta Pharma	ICICI Direct Target	2800.50	1950.00	1615.75 (73.33%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	06 May 2023	Ajanta Pharma	Motilal Oswal Target	2800.50	1490.00	1298.45 (115.68%)	Target met	Buy	pdf post cache		Broker Report Disruption in Africa segment/higher opex drags earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	06 May 2023	Ajanta Pharma	ICICI Direct Target	2800.50	1520.00	1298.45 (115.68%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	06 May 2023	Ajanta Pharma	BOB Capital Markets Ltd. Reco Target	2800.50	1520.00	1298.45 (115.68%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Margins appear to have bottomed out; raise to BUY BOB Capital Markets Ltd. Strong India and US growth in Q4 (17% YoY each) offset by declines in other businesses pdf Copy Link Share on Share on Share on Share on Alert
	10 Mar 2023	Ajanta Pharma	Motilal Oswal Target	2800.50	1410.00	1219.90 (129.57%)	Target met	Buy	pdf post cache		Broker Report Healthy Work-in-progress on reducing cost pressure to boost outlook Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners